Abstract: A method for ascertaining an emotional goal includes receiving, via an emotionally responsive computerized system having a user interface communicatively coupled to a networked user device including a processor device, user-input concerning a purpose of a user's interaction with a software interface. It can include registering input indicating a target person to whom the purpose of the user's interaction pertains and prompting the user to provide a root motivator comprising a root emotion or a root reason for the interaction. Some variations include generating a user-perceptible output and a set of user interface elements dependent on the root motivator along with obtaining the user's specific emotional goal with respect to the target person on the basis of user-inputs in response to a presentation of a sequence of user interface elements, to provide the user, via the software interface, a recommendation regarding a fulfillment of the specific emotional goal.

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are biomimetic osteochondral implants that are generally useful for the at least partial resurfacing of damaged cartilage within a joint. The implants are constructed to have a modular, layered structure in which the physical properties (e.g., stiffness and lubricity) or dimensions of each layer can be adjusted (e.g., by using the appropriate material and controlling the thickness thereof) based on the anatomy to be replaced. For example, the material and or thicknesses of the layers can be selected to approximate the physical properties and/or dimensions of cartilage (and, optionally, chondral and subchondral bone). Also provided herein are methods of treatment involving the use of said biomimetic osteochondral implants to repair an osteochondral defect in a joint.

Abstract: A method of manufacturing a pressure vessel (10) comprising the steps of dividing a wall (104) of a section (100) of the pressure vessel (10) into a first segment (120) and a second segment (150), separating the first segment (120) from the second segment (150), fitting apparatus (400) onto the first segment (120), and then re-attaching the first segment (120) and the second segment (150).

Abstract: Systems, methods, and computer-readable media are described for compact radar systems. In some examples, a compact radar system can include a first set of transmit antennas, a second set of receive antennas, one or more processors, and at least one computer-readable storage medium storing computer-executable instructions which, when executed by the one or more processors, cause the radar system to coordinate digital beam steering of the first set of transmit antennas and the second set of receive antennas, and coordinate digital beam forming with one or more of the second set of receive antennas to detect one or more objects within a distance of the radar system.

Abstract: A method of inverting workpieces in a mass production process includes: advancing an end effector in electronic synchronization with advancement of a carrier to synchronize arrival of the carrier at a stop position with arrival of the end effector at an unloading position, in which the end effector is in alignment with a workpiece held by the carrier for engaging the workpiece; while the end effector is in engagement with the workpiece, retracting the end effector away from the carrier to unload the workpiece from the carrier and advancing the end effector back toward the carrier to load the workpiece back into the carrier; and rotating the end effector relative to the carrier to invert the workpiece in electronic synchronization with the retracting and advancing of the end effector for loading the workpiece back into the carrier when inverted.

Abstract: Structured data comprising primary data is transformed into object-based data comprising the primary data and at least one search function. The object-based data when loaded into memory provides the search function as executable instructions for an object instance. When an application calls the object instance with search terms as input, the search terms are located within the primary data (which is loaded into memory) by the search function, and the object instance returns corresponding field values from the primary data associated with the search terms to the application.

Abstract: A manufacturing method is provided. During this method, a preform component is provided for a turbine engine. The preform component includes a substrate. A meter section of a cooling aperture is formed in the substrate. An internal coating is applied onto a surface of the meter section. An external coating is applied over the substrate. A diffuser section of the cooling aperture is formed in the external coating and the substrate to provide the cooling aperture.

Abstract: A manufacturing method is provided during which a preform component for a turbine engine is provided. The preform component includes a substrate and a locating feature at an exterior surface of the substrate. An outer coating is applied over the substrate. The outer coating covers the locating feature. At least a portion of the preform component and the outer coating are scanned with an imaging system to provide scan data indicative of a location of the locating feature. A cooling aperture is formed in the substrate and the outer coating based on the scan data.

Abstract: The present invention relates to the use of cannabidiol (CBD) and an anti-epileptic drug (AED), brivaracetam (BRV), for the treatment of seizures associated with epilepsy syndromes. In particular the types of seizures treated include atonic, tonic, tonic-clonic, and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with herpes simplex virus. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, myoclonic, absence and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to a method of treating seizures using cannabidiol (CBD), which significantly shortens the dose titration period. This results inpatients receiving maintenance doses sooner after initiating treatment, which reduces the occurrence of breakthrough seizures and improves adherence to treatment.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with encephalocele. In a further embodiment the types of seizures include absence, focal seizures with secondary generalisation and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with a SPATA5 mutation. In a further embodiment the types of seizures include tonic, myoclonic and focal seizures with impairment. Preferably the dose of CBD is between mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidivarin (CBDV) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Rett syndrome. In a further embodiment the types of seizures include focal motor seizures with impairment, focal non-motor seizures with impairment, generalised motor seizures, generalised non-motor seizures, unknown onset motor seizures, and non-motor seizures. Preferably the dose of CBDV is between 2.5 mg/kg/day to 10 mg/kg/day.

Abstract: Provided herein are biomimetic osteochondral implants that are generally useful for the at least partial resurfacing of damaged cartilage within a joint. The implants are constructed to have a modular, layered structure in which the physical properties (e.g., stiffness and lubricity) or dimensions of each layer can be adjusted (e.g., by using the appropriate material and controlling the thickness thereof) based on the anatomy to be replaced. For example, the material and or thicknesses of the layers can be selected to approximate the physical properties and/or dimensions of cartilage (and, optionally, chondral and subchondral bone). Also provided herein are methods of treatment involving the use of said biomimetic osteochondral implants to repair an osteochondral defect in a joint.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes related to brain injury. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with hypoxic ischaemic encephalopathy (HIE) or anoxia at birth. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, myoclonic, absence, focal seizures with impairment and spasms. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients with PURA gene mutation. In a further embodiment the types of seizures include tonic, atonic and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with SYNGAP1 gene mutation. In a further embodiment the types of seizures include atonic and absence seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with PCDH19 Epilepsy. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.